OpGen (OPGN) Downgraded by Zacks Investment Research to Hold

OpGen (NASDAQ:OPGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday, February 16th.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Other equities research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of OpGen in a research note on Wednesday, November 8th. ValuEngine raised OpGen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

Shares of OpGen (OPGN) traded down $0.13 during mid-day trading on Friday, hitting $2.27. The company had a trading volume of 326,408 shares, compared to its average volume of 451,214. OpGen has a 52-week low of $1.78 and a 52-week high of $31.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.23 and a quick ratio of 1.13. The company has a market cap of $12.00, a price-to-earnings ratio of -0.15 and a beta of 1.21.

An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. raised its position in shares of OpGen Inc (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 as of its most recent filing with the Securities & Exchange Commission.

ILLEGAL ACTIVITY NOTICE: This piece was posted by BBNS and is owned by of BBNS. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://baseballnewssource.com/2018/03/14/opgen-opgn-cut-to-hold-at-zacks-investment-research/1890657.html.

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.